BDNF and Parkinson disease: In the animal models of PD, BDNF brain content was augmented through direct injection of BDNF [88,89], gene transduction by viral vectors [90,91,92,93,94], or delivery via nonviral carriers [95,96] and also via secretion from genetically engineered cells [97,98,99,100,101].